Compound repurposing
Small molecule compounds are being studied for repurposing in COVID-19 treament and research. Multiple small molecules that are approved to treat other disorders have shown potential effects on key proteins involved in SARS-CoV-2 host cell entry and replication. Repurposing of existing compounds is advantageous for speed - reducing timescales compared to conventional drug discovery. Researchers can save up to 50% on these small molecules for COVID-19 research, as they are up to half the price of other suppliers.
Mibefradil dihydrochloride (HB1226)
Description:Potent, reversible T- / L-type Ca2+ channel blocker
Purity:>95%
ω-Agatoxin IVA (HB1212)
Description:Potent, selective P-type / Q-type Ca2+ channel blocker
Purity:>95%
SNX 482 (HB1235)
Description:Reported to be a potent, selective Cav2.3 (R-type) channel blocker
Purity:>95%
TTA-P2 (HB5851)
Description:Potent, selective, reversible T-type calcium channel blocker
Purity:>98%